Evidence map›Paper›PMID 42401703›Full record

ArticleEMBO reports2026

PARG inhibition reduces ssDNA levels and limits RPA loading upon replication fork collapse.

Alexandra Mihuț, Debanjan Ghosh, Adrián Kószó, Dávid Szüts, Sarka Andrs Salajkova, Martin Andrs, Jana Dobrovolna, Roberta Fajka-Boja, Gyula Timinszky

Abstract read
In one paragraph

Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexandra MihuțLaboratory of DNA Damage and Nuclear Dynamics, Institute of Genetics, HUN-REN Biological Research Centre, H-6726, Szeged, Hungary.ORCID 0000-0002-6577-4440
Debanjan GhoshLaboratory of DNA Damage and Nuclear Dynamics, Institute of Genetics, HUN-REN Biological Research Centre, H-6726, Szeged, Hungary.ORCID 0000-0001-7220-9928
Adrián KószóLaboratory of DNA Damage and Nuclear Dynamics, Institute of Genetics, HUN-REN Biological Research Centre, H-6726, Szeged, Hungary.ORCID 0009-0001-9252-7402
Dávid SzütsInstitute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, H-1117, Budapest, Hungary.ORCID 0000-0001-7985-0136
Sarka Andrs SalajkovaInstitute of Molecular Cancer Research, University of Zurich, Strickhofstrasse 40a, 8057, Zurich, Switzerland.
Martin AndrsInstitute of Molecular Cancer Research, University of Zurich, Strickhofstrasse 40a, 8057, Zurich, Switzerland.
Jana DobrovolnaDepartment of Genome Biology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague 4, Czech Republic.
Roberta Fajka-BojaLaboratory of DNA Damage and Nuclear Dynamics, Institute of Genetics, HUN-REN Biological Research Centre, H-6726, Szeged, Hungary. fajka_boja.roberta@brc.hu.ORCID 0000-0001-5331-8280
Gyula TiminszkyLaboratory of DNA Damage and Nuclear Dynamics, Institute of Genetics, HUN-REN Biological Research Centre, H-6726, Szeged, Hungary. timinszky.gyula@brc.hu.ORCID 0000-0001-6342-8985

Funding

Czech Science Foundation 21-22593XCzech Science Foundation 26-22773MNational Research, Development and Innovation Office K142385National Research, Development and Innovation Office K143248
6 · The paper itself

Abstract

Poly(ADP-ribosyl)ation (PARylation) is a transient post-translational modification catalyzed by PARP enzymes and reversed by PARG. PARG inhibition causes sustained PARylation and is being explored as an anticancer strategy, but its cellular consequences remain incompletely understood. Here, we examine how persistent PARylation influences cellular responses to replication stress and DNA damage. We show that sustained PARylation reduces phosphorylated and chromatin-bound RPA most strongly under fork-stalling conditions that progress toward fork collapse. This effect requires PARP1 activity and is restrained by intact ATR-CHK1 signaling, as checkpoint inhibition renders otherwise resistant cells permissive for PARG inhibitor-associated phosphorylated RPA loss from the chromatin. The reduction of RPA phosphorylation is not dependent on BRCA1 and it is not accompanied by increased RAD51 loading. Instead, reduced chromatin-bound RPA coincides with decreased exposed ssDNA. Our results identify a checkpoint-dependent fork-collapse state in which sustained PARylation limits ssDNA and RPA levels.

Indexed as

DNA ReplicationDNA, Single-StrandedReplication Protein AAtaxia Telangiectasia Mutated ProteinsBRCA1 ProteinCheckpoint Kinase 1ChromatinDNA DamageHumansPhosphorylationPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) PolymerasesPoly ADP RibosylationProtein KinasesRad51 RecombinaseSignal TransductionAtaxia Telangiectasia Mutated ProteinsATR protein, humanBRCA1 ProteinCheckpoint Kinase 1CHEK1 protein, humanChromatinDNA, Single-StrandedPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) PolymerasesProtein KinasesRad51 RecombinaseReplication Protein A

Identifiers

PMID42401703
PMCPMC13503914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.